Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

How we treat patients with metastatic HER2-positive breast cancer

(2022) G. Nader-Marta et al.   ESMO Open

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

(2021) Volkmar Mueller et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

(2021) Erica Michelle Stringer-Reasor et al.   JOURNAL OF CLINICAL ONCOLOGY

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies

(2021) Alejandro Garcia-Alvarez et al.   Cancers

Current and Future Management of HER2-Positive Metastatic Breast Cancer

(2021) Olga Martínez-Sáez et al.   JCO Oncology Practice

Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases

(2021) Albert E Kim et al.   Neuro-Oncology Practice

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

(2021) Michael A. Vogelbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

How we treat HER2-positive brain metastases

(2021) E. Stavrou et al.   ESMO Open

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

(2021) G. Curigliano et al.   ANNALS OF ONCOLOGY

Exclusion of patients with brain metastases from cancer clinical trials

(2020) Roshal R Patel et al.   NEURO-ONCOLOGY

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

(2020) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) William J. Gradishar et al.   Journal of the National Comprehensive Cancer Network

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

(2020) Anita Kulukian et al.   MOLECULAR CANCER THERAPEUTICS

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆

(2020) F. Montemurro et al.   ANNALS OF ONCOLOGY

The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer

(2020) Aena Patel et al.   Cancers

Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer

(2020) Lauriane Eberst et al.   CURRENT OPINION IN ONCOLOGY

Treatment strategies for breast cancer brain metastases

(2020) Caroline Bailleux et al.   BRITISH JOURNAL OF CANCER

Systemic Therapy of Central Nervous System Metastases of Breast Cancer

(2019) José Pablo Leone et al.   Current Oncology Reports

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs

(2018) Sara A. Hurvitz et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

(2018) Michael Lux et al.   Cancers

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group

(2017) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

(2014) I. E. Krop et al.   ANNALS OF ONCOLOGY

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

(2013) Bernhard C Pestalozzi et al.   LANCET ONCOLOGY

HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions

(2011) K.A.B. Goddard et al.   Public Health Genomics